BioSpace News Archive

Medical Group Management Association (MGMA) is pleased to welcome Akash Madiah as the organization’s new Chief Financial Officer.

IQ-AI (formerly Flying Brands Limited) has filed a patent for gadolinium-free MR imaging of the brain and other organs.

Health Catalyst, Inc., a leader in next-generation data, analytics, and decision support, announced four new members of its leadership team

AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, today publishes data in the prestigious Journal of the American Medical Association (JAMA) of its recently completed STOP-AKI Phase II study of recAP

DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the presentation of a clinical research abstract at the 37th Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new antiviral program at the upcoming World Antimicrobial Resistance (AMR) Congress

Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural food ingredient company, today announced that it will release its third-quarter 2018 financial and business results after market close on November 7, 2018.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV:COV) (OTCQX:CVALF), an advanced medical technologies company, today announces that it will be showcasing newly-acquired moisture barrier line AquaGuard® as part of its portfolio of infection prevention products at the 2018 American Nurses Credentialing Center National Magnet Conference

“Ray has been working with us as an advisor for two years, and we are thrilled to have him join us full time as we expand our focus on biologics drug discovery,” said CEO Emily M. Leproust, Ph.D.

New Diagnostic Assay Intended to Identify Patients with ROS1, NTRK or ALK Gene Fusions for Treatment with TP Therapeutics’ Investigational Drug, Repotrectinib